This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
Cushing’s
Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps your body respond to stress.
A Cushing’s tale: Two images. Eight months. Same person.
January 6, 2022
To launch the eighth season of the Pituitary World News podcast, we welcome to our microphones, Brandy. Brandy has quite a story to tell us about her battle with Cushing’s disease.
Mifepristone (Korlym®)
December 9, 2021
In the last podcast in the series on the drugs available to manage hypercortisolism, Dr. Blevins discusses mifepristone, trade name Korlym®.
Pasireotide (Signifor, Signifor LAR)
December 8, 2021
This is the fourth podcast in a series of five on medications to treat Cushing’s disease. Today Dr. Blevins discusses Pasireotide, trade names Signifor and Signifor LAR.
Isturisa® (osilodrostat)
December 6, 2021
Our third podcast in the series is on osilodrostat (trade name Isturisa®), a drug approved by the FDA in the US and the European Medicines Agency (EMA) to treat hypercortisolism in patients who are not candidates for surgery or those that surgery did not work. In this podcast, Dr. BLevins takes us inside his clinical practice to share his experiences with the drug.
Metyrapone
December 3, 2021
The second podcast in our series on the medical management of hypercortisolism focuses on the drug metyrapone. Dr. Blevins discusses the drug uses, how it works, and its side effects.
Coming up next, a discussion on the drug Isturiza® (osilodrostat).
Ketoconazole
December 2, 2021
This is the first in our series of five podcasts on the medical management of Hypercortisolism due to Cushing’s disease. Today Dr. Blevins discusses the drug Ketoconazole. Tune in tomorrow to listen to the second podcast in the series on the use of Metyrapone, and on Monday, don’t miss the podcast on Isturisa® (osilodrostat).
Medications for Cushing’s disease: a review.
December 1, 2021
We are pleased to announce a series of podcasts on the medical management of hypercortisolism.
The challenges and opportunities in new hypercortisolism drugs
November 17, 2021
Today we welcome three renowned experts in the development of drugs to treat hypercortisolism. Dr. Blevins and I discuss their research, clinical trials, challenges, and opportunities for these essential medications that could immensely affect patient well-being and quality of life. This discussion touches on the fascinating details of hypercortisolism and the developments now and in the future.
The postoperative evaluation and management of patients with hypercortisolism
October 12, 2021
Dr. Lewis Blevins’ discussion on the postoperative evaluation and management of patients with hypercortisolism is technical and directed to physicians, but we encourage everyone to listen to it.
October is Pituitary Awareness Month.
September 29, 2021
From the editor’s desk – For organizations in the pituitary space, we believe it is critically important to reach out to a broader audience to make the case that these conditions, although classified as rare,
Cushing’s disease and syndrome: The evolving story of hypercortisolism
April 16, 2021
How is the emerging knowledge of hypercortisolism influencing how Cushing's disease and syndrome are understood and affecting the practice and those working on the front lines doing the work and caring for patients? In this
How Cushing’s Disease Helped Shape Sharmyn’s Wonderful Life
April 7, 2021
On Cushing’s Day, we share Sharmyn McGraw’s blog on her journey with the disease. From her Blog – “Now twenty-one years in remission from a pituitary adenoma tumor, Sharmyn McGraw, patient advocate, author, artist, and